Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats

Digestive Diseases and Sciences

Volumn 50, Issue SUPPL. 1, 2005, Pages

  Nakashima, Takako ^a   Maeda, Takashi ^a   Nagamoto, Hisashi ^a   Kumakura, Takeshi ^a   Takai, Masaaki ^a   Mori, Toyoki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Colitis; Dextran sulfate sodium; Enema; Rat; Rebamipide; T84

Indexed keywords

DEXTRAN SULFATE; ENEMA; MESALAZINE; REBAMIPIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL MEMBRANE RESISTANCE; COLON CANCER; COLON INJURY; COLON MUCOSA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTRIC RESISTANCE; EXPERIMENTAL MODEL; FECES ANALYSIS; HEMATOCHEZIA; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STAINING; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ALANINE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; COLITIS, ULCERATIVE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENEMA; INDICATORS AND REAGENTS; MALE; MESALAMINE; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 25644432759     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2817-0     Document Type: Article

References (35)

1. Farmer RG: In JE Berk (ed). Bockus Gastroenterology, 4th ed. Philadelphia, WIS Saunders, 1985, pp 60
2. Hibi T, Ogata H, Sakuraba A: Animal models of inflammatory bowel disease. J Gastroenterol 37:409-417, 2002
3. Ohkusa T: Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and change in intestinal microflora. Jpn J Gastroenterol 82:1327-1336, 1985
4. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702, 1990
5. Kimura I, Kamiya A, Nagahama S, Yoshida J, Tanigawa H, Kataoka M: Study on the experimental ulcerative colitis model induced by dextran sulfate sodium in rat: estimation of mucosal erosions by the alcian blue-staining method. Folia Pharmacol Jpn 102:343-350, 1993
6. Kimura I, Nagahama S, Kawasaki M, Kamiya A, Kataoka M: Study on the experimental ulcerative colitis (UC) model induced by dextran sulfate sodium (DSS) in rats (2). Folia Pharmacol Jpn 105:145-152, 1995
7. Kimura I, Nagahama S, Kawasaki M, Kataoka M, Sato M: Study on the experimental ulcerative colitis (UC) model induced by dextran sulfate sodium (DSS) in rats (3). Folia Pharmacol Jpn 108:259-266, 1996
8. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S: Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 142:23-29, 1987
9. Uchida M, Tabusa F, Komatsu M, Morita S, Kanbe T, Nakagawa K: Studies on 2 (1H)-quinolinone derivatives as gastric antiulcer active agents. Synthesis and antiulcer activities of optically active alpha-amino acid derivatives of 2 (1H)-quinolinone and oxindole. Chem Pharm Bull (Tokyo) 35:853-856, 1987
10. Higuchi K, Arakawa T, Nebiki H, Uchida T, Fujiwara Y, Ando K, Yamasaki K, Takaishi O, Fukuda T, Kobayashi K, Kuroki T: Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci 43:99S-106S, 1998
11. Yoshikawa T, Naito Y, Tanigawa T, Kondo M: Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 43:363-366, 1993
12. Nagano C, Wakebe H, Azuma A, Imagawa K, Kikuchi M: IFN-gamma-induced iNOS mRNA expression is inhibited by rebamipide in murine macrophage RAW264.7 cells. Dig Dis Sci 43:118S-124S, 1998
13. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M: Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci 43:160S-166S, 1998
14. Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M: Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 41:1139-1144, 1996
15. Kim CD, Kim YK, Lee SH, Hong KW: Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappa B-dependent pathway. J Pharmacol Exp Ther 294:864-869, 2000
16. Yoshida M, Wakabayashi G, Ishikawa H, Kitahora T, Otani Y, Shimazu M, Miura S, Ishii H, Kitajima M: Rebamipide attenuates gastric microcirculatory disturbances in the early period after thermal injury in rats. Dig Dis Sci 43:148S-153S, 1998
17. Kobayashi T, Zinchuk VS, Garcia del Saz E, Jiang F, Yamasaki Y, Kataoka S, Okada T, Tsunawaki S, Seguchi H: Suppressive effect of rebamipide, an antiulcer agent, against activation of human neutrophils exposed to formyl-methionyl-leucyl-phenylalanine. Histol Histopathol 15:1067-1076, 2000
18. Kim CD, Hong KW: Preventive effect of rebamipide on gastric lesions induced by ischemia-reperfusion in the rat. J Pharmacol Exp Ther 275:340-344, 1995
19. Kleine A, Kluge S, Peskar BM: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441-9, 1993
20. Sun WH, Tsuji S, Tsujii M, Gunawan ES, Kawai N, Kimura A, Kakiuchi Y, Yasumaru M, Iijima H, Okuda Y, Sasaki Y, Hori M, Kawano S: Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther 295:447-452, 2000
21. Suetsugu H, Ishihara S, Moriyama N, Kazumori H, Adachi K, Fukuda R, Watanabe M, Kinoshita Y: Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med 136:50-57, 2000
22. Takahashi M, Takada H, Takagi K, Kataoka S, Soma R, Kuwayama H: Gastric restitution is inhibited by dexamethasone, which is reversed by hepatocyte growth factor and rebamipide. Alim Pharmacol Ther 18:126-132, 2003
23. Watanabe T, Higuchi K, Hamaguchi M, Tanigawa T, Wada R, Tominaga K, Fujiwara Y, Arakawa T: Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori infection in Mongolian gerbils. Dig Dis Sci 47:1582-1589, 2002
24. Zea-Iriarte WL, Makiyama K, Goto S, Murase K, Urata Y, Sekine I, Hara K, Kondo T: Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis rats. Protective effect of rebamipide. Scand J Gastroenterol 31:985-992, 1996
25. Sakurai K, Osaka T, Yamasaki K: Protection by rebamipide against acetic acid-induced colitis in rats: relationship with its antioxidative activity. Dig Dis Sci 43:125S-133S, 1998
26. Iwai A, Iwashita E: Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig Dis Sci 43:143S-147S, 1998
27. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y: Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608-1616, 2000
28. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 95:1838-1839, 2000
29. Cooper HS, Murthy SNS, Shan RS, Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238-249, 1993
30. Madara JL, Dharmsathaphorn K: Occluding junction structure-function relationships in a cultured epithelial monolayer. J Cell Biol 101:2124-2133, 1985
31. Madara JL, Stafford J: Structural analysis of a human intestinal epithelial cell line. Gastroenterology 92:1133-1145, 1987
32. Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 43:90S-98S, 1998
33. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: Overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43:5S-13S, 1998
34. Banan A, Fitzpatrick L, Zhang Y, Keshavarzian A: OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability. Free Radic Biol Med 30:287-298, 2001
35. Prakash A, Markham A: Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease. Drugs 57:383-408, 1999